Amlodipine Besylate Tablets recalled over manufacturing violations
- Recall date
- September 17, 2013
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Mylan Institutional, Inc. (d.b.a. UDL Laboratories) recalls Amlodipine Besylate Tablets, USP, 2.5 mg*, packaged in a)100-count (10 x 10) unit dose blisters per carton, NDC 51079-4…
- Recall number
- D-1466-2016
- FDA classification
- Class II
- Brand / firm
- Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
- Sold / distributed
- Nationwide, Puerto Rico and Guam
Why it was recalled
CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Amlodipine Besylate Tablets, USP, 2.5 mg*, packaged in a)100-count (10 x 10) unit dose blisters per carton, NDC 51079-450-20 and b) 30-count tablets per dosage card in a carton, NDC 51079-450-63, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505; Packaged and Distributed By: UDL Laboratories, Inc., Rockford, IL 61103.
Get recall alerts
Free email alert whenever Mylan Institutional, Inc. (d.b.a. UDL Laboratories) has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Mylan Institutional, Inc. (d.b.a. UDL Laboratories)